Association of circulating protein biomarkers with clinical outcomes of durvalumab in head and neck squamous cell carcinoma

The potential for durvalumab, a programmed cell death ligand-1 (PD-L1)-blocking monoclonal antibody, to treat head and neck squamous cell carcinoma (HNSCC) is being evaluated in multiple clinical trials. We assessed circulating proteins at baseline to identify potential biomarkers and to understand...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Oncoimmunology 2021-01, Vol.10 (1), p.1898104-1898104
Hauptverfasser:	Arends, Rosalinda, Guo, Xiang, Baverel, Paul G., González-García, Ignacio, Xie, James, Morsli, Nassim, Yovine, Alejandro, Roskos, Lorin K.
Format:	Artikel
Sprache:	eng
Schlagworte:	Biomarker durvalumab head and neck squamous cell carcinoma immune checkpoint inhibitor Original Research overall survival
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!